Gefurulimab Improves Symptoms in Myasthenia Gravis
The investigational once-weekly nanobody significantly improved symptoms in adults with generalized myasthenia gravis in a phase III trial.
Updated on Nov. 10, 2026 in Stroke

The PREVAIL phase III, double-blind, placebo-controlled trial found that gefurulimab significantly improved symptoms in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Gefurulimab is an investigational once-weekly subcutaneous nanobody.
Why it matters
Generalized myasthenia gravis causes muscle weakness that can be disabling, and a weekly subcutaneous option could ease access for patients who currently depend on infusion center visits. The results add a new candidate to the treatment options under study for this condition.
The phase III PREVAIL trial reported a 4.2-point MG-ADL reduction for gefurulimab versus a 2.1-point reduction on placebo, with significance reached within one week. Sample size and longer-term outcomes were not stated in the available data.
The players
Gefurulimab
An investigational once-weekly subcutaneous nanobody, a smaller molecule than monoclonal antibodies, being evaluated for generalized myasthenia gravis.
The details
Gefurulimab was given once weekly by subcutaneous injection alongside intravenous immunoglobulin, with patients on stable dosages. Adverse event rates were similar to placebo, with slightly more mild-to-moderate injection-site reactions in the gefurulimab group and no meningococcal infections.
Timeline
Results of the PREVAIL trial were presented in November 2026.
Big Picture
The PREVAIL phase III results position gefurulimab as a new once-weekly option that could reduce the infusion-center burden seen with current myasthenia gravis therapies. The data extend the program's early evidence into a confirmatory phase III setting.
For people with generalized myasthenia gravis, a once-weekly injection could reduce how often they need infusion center visits if the drug is approved. Patients should discuss any new treatment with their own neurologist before making changes.
The takeaway
Trial results showing symptom improvement within a week suggest faster relief is possible in this condition. Readers with myasthenia gravis should track how new options compare with their current treatment plan.
Further reading
Explore more Stroke coverage for related neurological care context.







